382150.Kq
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 10,808,834,910, which is significantly higher than its total liabilities of KRW 650,874,290, resulting in a current ratio of 24.47. The price-to-book ratio of 5.27 and a debt-to-equity ratio of 0.01 indicate a low financial leverage and a strong equity base.
Profitability metrics are negative, with a return on equity of -33.35% and a return on assets of -32.05%, reflecting a substantial net loss of KRW 5,369,587,680. These figures are well below the industry median for profitability, suggesting the company is underperforming in terms of generating returns on its equity and assets.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks if the segment faces challenges.
The company is currently experiencing a significant decline in performance, with a net loss of KRW 5,369,587,680 and a negative operating income of KRW 5,716,983,610. These figures suggest a challenging growth trajectory, with no clear signs of improvement in the near term.
Risk factors include a high liquidity risk due to negative operating and free cash flows, although the company's strong cash reserves mitigate this to some extent. The risk of dilution is currently low, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow could necessitate future equity issuance, which would increase dilution risk.
Recent events include the publication of the latest financial report, which highlights the company's significant net loss and negative operating income. No recent filings or transcripts indicate any major strategic shifts or new product launches that could alter the company's trajectory.
- The company has a strong liquidity position with a current ratio of 24.47 and a debt-to-equity ratio of 0.01.
- Profitability is severely negative, with a return on equity of -33.35% and a return on assets of -32.05%.
- The company's revenue is concentrated in a single business segment, increasing operational risk.
- The company is experiencing a significant decline in performance, with a net loss of KRW 5,369,587,680.
- Liquidity risk is high due to negative operating and free cash flows, although strong cash reserves provide some buffer.
- The risk of dilution is currently low, but the company's financial performance could necessitate future equity issuance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 382150.KQ Market data — financials · 2026-05-26